Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

Background:

Drugs like nalmefene interfere with opioid receptors. This might reduce drinking. The gene OPRM1 determines opioid receptor functions. Researchers want to see if nalmefene affects people s responses to alcohol cues. They also want to compare how nalmefene affects people with different forms of OPRM1.

Objectives:

To test nalmefene s effects on alcohol self-infusion and responses to alcohol cues. To test the role of different forms of OPRM1 on these effects.

Eligibility:

Healthy heavy drinkers ages 21 60:

Women: over 15 drinks weekly

Men: over 20 drinks weekly

Design:

Participants will be screened with:

Medical history

Physical exam

Heart, blood, and urine tests

Questionnaires

Participants will have three 10-hour visits and one 2-hour follow-up visit. They will take a taxi. Visits are about 1 week apart.

Before visits, participants cannot drink alcohol for 1 day or take medicine for 3 days.

All study visits:

Questionnaires

Heart monitor

Two-hour alcohol session: A needle guides a thin plastic tube into a vein in each arm. One tube receives alcohol. The other draws blood. Participants give themselves alcohol by pressing a button on a computer.

Relaxing at the center until breath alcohol falls below 0.02 percent, or for 3 hours.

Visits 2 and 3:

Swallowing nalmefene or placebo.

One-hour brain MRI: Participants lie on a table with a coil on their head. They press buttons in response to computer cues.

Follow-up visit: participants will discuss their drinking habits.

Study Overview

• Status: Completed
• Conditions: AUD
• Intervention / Treatment: Drug: Nalmefene; Other: Placebo

Detailed Description

Previous studies have shown that the opioid receptor modulator nalmefene can reduce heavy drinking among alcoholics. Genetic variation at the micro-opioid receptor gene locus, OPRM1, specifically the A118G polymorphism, is associated with differential subjective responses to alcohol. Further, the A118G polymorphism has been shown to moderate the effect of opioid receptor modulators on alcohol consumption. However, the role of A118G on nalmefene s effectivenes, and the neural substrates underlying nalmefene s therapeutic effect remain to be explored in humans.

Objective: To evaluate the effect of nalmefene on alcohol self-infusion and neural response to alcohol cues in healthy male and female heavy drinkers, and to examine the role of the OPRM1 A118G polymorphism on this effect.

Study population: Participants will be 21-60 year-old male and female heavy drinkers in good health, as determined by medical history, physical exam, and ECG and lab tests. Participants with current Axis-I mood, anxiety or substance use diagnoses, except alcohol dependence, will be excluded. Participants will be divided into 2 genotypic groups: Group 1 (AA) will include participants homozygous for the major 118A allele (118AA genotype), and group 2 (GX) will include participants carrying 1 or 2 copies of the variant 118G allele (118AG or 118GG genotype).

Design: Participants will undergo 3 study sessions. In the first session, participants will complete an intravenous alcohol self-administration (IV-ASA) where they will have an open bar phase to determine their baseline level of alcohol consumption in the laboratory, as well as to obtain data on tolerability and subjective measures of alcohol effects. In the second and third sessions, participants will receive a single dose of either nalmefene or placebo, in counter-balanced order, before completing functional magnetic resonance imaging (fMRI) scans and IV-ASA procedures. The fMRI scans will include a task where participants will see cues that indicate the possibility of earning alcohol rewards to examine the neural substrates involved in processing alcohol cues, and a task designed to measure neural responses during anticipation and processing of aversive events. The difference in alcohol self-infusions between the two sessions will be compared between the two genotypic groups.

Outcome measures: The primary outcome measures are: (1) nalmefene-induced changes in IV alcohol self-administration; (2) nalmefene-induced BOLD signal changes in neural regions associated with alcohol reward processing, including ventral striatum, amygdala, and insula.;Secondary outcome measures include: (1) Nalmefene-induced BOLD signal changes in neural processing of aversive stimuli during fMRI; (2) Genotypic modulation (at the OPRM1 118 location) of nalmefene s effects on primary outcome measures (BOLD signal change during alcohol reward processing and IV alcohol self-administration).

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Vijay A Ramchandani, Ph.D.; Phone Number: (301) 402-8527; Email: NIAAASHPResearch@mail.nih.gov

Study Locations

• United States
  • Maryland
    • Bethesda, Maryland, United States, 20892
      • National Institutes of Health Clinical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

• ELIGIBILITY CRITERIA:

Participants will be healthy 21-60 year-old male and female heavy drinkers. An equal number of participants with OPRM 118 AA genotype and those with 1 or 2 copies of the G allele (AG or GG) will be enrolled. Inclusion and exclusion criteria will be evaluated following screening conducted under the NIAAA screening protocol as described below

INCLUSION:

• Male and female participants between 21-60 years of age.
• Male participants must have consumed an average of greater than 14 standard drinks per week, and females must have consumed an average of greater than 7 standard drinks per week during the past 3 months [assessment: 90-day timeline followback (TLFB)completed at screening visit].
• In addition, participants must have on average at least 1 binge drinking day per week during the last 90 days, defined as a day in which 4 or more standard drinks were consumed for females and 5 or more standard drinks were consumed for males. Average number of binge drinking days will be calculated based on total number of binge drinking days from the TLFB (e.g., for 90 days worth of data, participants with a total of 13 or more binge drinking days will be eligible).
• Participants must be willing and able to refrain from using alcohol one day prior to each study, and non-prescription medication for 3 days prior to each visit [assessment: medical history].

• Inclusion criteria for women:

  • Use of adequate method of birth control during the study, if female is sexually active and is not surgically sterilized. Adequate methods of contraception include: use of oral contraceptives; use of barrier method of contraceptive; use of an approved IUD or other long-acting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively female sexual partner(s) [assessment: medical history].

EXCLUSION:

• Current or prior history of major medical illness, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders [assessment: clinically significant findings on medical history and physical exam, ECG, laboratory tests].
• Participation in any other pharmacological intervention study within 4 months prior to the start of this study [assessment: medical history].
• Positive hepatitis A, B Antigen, or C, or HIV test [assessment: laboratory test].
• An aspartate transaminase (AST) / alanine transaminase (ALT) ratio 3 times greater than the normal limit [assessment: laboratory test].
• Diagnosis of Axis-I anxiety disorders or major depressive disorders in the past 12 months [assessment: SCID interview].
• Lifetime diagnosis of Axis-I bipolar disorders or psychotic disorders [assessment: SCID interview].
• Suicidal ideation in the past 6 months or suicidal behavior in the past 12 months [assessment: Columbia Suicide Severity Rating Scale].
• Current diagnosis of substance use disorder (SUD), other than alcohol use disorder, mild cannabis use disorder (less than 4 criteria), or current SUD in remission. Current smoking or nicotine dependence is not exclusionary [assessment: SCID-IV/SCID-5 interview, FTND].
• Positive result on urine drug screen or breathalyzer test during screening. Positive urine drug screen or breathalyzer reading during more than 1 study visit will result in participant withdrawal from the study [assessment: laboratory tests and breathalyzer test performed at screening or update visit under 14-AA-0181 most proximal to enrollment].
• Currently (i.e., at the time of screening) seeking treatment for alcohol problems or have undergone inpatient or outpatient detoxification or treatment for alcohol problems in the past 6 months. [assessment: medical history and physical exam].
• Lactose intolerance or rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption [assessment: medical history and physical exam].

• Alcohol use:

  • Current or prior history of alcohol-induced flushing reaction, including rapid reddening of the face, rapid heart rate and breathing, and nausea after 1 or 2 drinks [assessment: medical history and physical exam, alcohol flushing questionnaire].
  • History of delirium tremens, hallucinations or seizures related to alcohol withdrawal [assessment: medical history, CIWA-Ar, SCID interview].

• Medication exclusion criteria:

  • Any regular or prescribed use of opioid analgesics in the past 3 months.
  • Use of prescription or OTC medications known to interact with alcohol within 2 weeks of the study. These include, but may not be limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, anti-epileptics including phenytoin and phenobarbital codeine, opioid analgesics including darvocet, percocet and hydrocodone, cough-and-cold preparations which contain anti-histamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen.
  • Use of medications known to inhibit or induce enzymes that metabolize alcohol for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram.
  • Use of drugs known to affect hemodynamic response. These include antihypertensives, insulin and thyroid medications. [assessment: medical history and physical exam].

• Exclusion criteria for MRI:

  • Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (including but not limited to pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments).
  • Fear of enclosed spaces.
  • Inability to lie comfortable on back for up to 2 hours in the MRI scanner [assessment: NIAAA MRI Safety Screening Questionnaire].

• Exclusion criteria for women:

  • Pregnant [assessment: urine beta-hCG test at screening]. Women must also test negative on urine beta-hCG test at the start of every study visit.
  • Breast-feeding [assessment: medical history and physical exam].

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Drug; single dose nalmefene	Drug: Nalmefene; Active Drug
Placebo Comparator: Placebo; single dose placebo	Other: Placebo; Single Dose Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nalmefene-induced BOLD signal changes in neural regions associated with alcohol reward processing, including ventral striatum, amygdala, and insula	functional MRI measure of brain activation.	Post-administration
Nalmefene-induced changes in IV alcohol self-administration	human laboratory alcohol consumption measure.	Post-administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nalmefene-induced BOLD signal changes in neural processing of aversive stimuli during fMRI	functional MRI measure of brain activation.	Post-adminstration
Genotypic modulation (at the OPRM1 118 location) of Nalmafene's effects on primary outcome measures (BOLD signal change during alcohol reward processing and IV alcohol self-administration).	human laboratory alcohol consumption measure.	Post-administration

Collaborators and Investigators

• Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Investigators: Principal Investigator: Vijay A Ramchandani, Ph.D., National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Publications and helpful links

Helpful Links

• NIH Clinical Center Detailed Web Page

Study record dates

Study Major Dates

• Study Start (Actual): June 8, 2016
• Primary Completion (Actual): December 8, 2023
• Study Completion (Actual): December 8, 2023

Study Registration Dates

• First Submitted: December 23, 2015
• First Submitted That Met QC Criteria: December 23, 2015
• First Posted (Estimated): December 24, 2015

Study Record Updates

• Last Update Posted (Actual): March 8, 2024
• Last Update Submitted That Met QC Criteria: March 7, 2024
• Last Verified: December 8, 2023

More Information

Terms related to this study

• Keywords: Genetics; fMRI; Nalmefene; Alcohol Infusion study; NIAAA
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Alcohol-Related Disorders; Substance-Related Disorders; Alcoholic Intoxication; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Narcotic Antagonists; Nalmefene
• Other Study ID Numbers: 160037; 16-AA-0037

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No